Your browser doesn't support javascript.
loading
A gene signature can predict risk of MGUS progressing to multiple myeloma.
Sun, Fumou; Cheng, Yan; Ying, Jun; Mery, David; Al Hadidi, Samer; Wanchai, Visanu; Siegel, Eric R; Xu, Hongwei; Gai, Dongzheng; Ashby, Timothy Cody; Bailey, Clyde; Chen, Jin-Ran; Schinke, Carolina; Thanendrarajan, Sharmilan; Zangari, Maurizio; Janz, Siegfried; Barlogie, Bart; Van Rhee, Frits; Tricot, Guido; Shaughnessy, John D; Zhan, Fenghuang.
Afiliación
  • Sun F; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Cheng Y; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Ying J; Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Mery D; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Al Hadidi S; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Wanchai V; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Siegel ER; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Xu H; Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Gai D; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Ashby TC; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Bailey C; Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Chen JR; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Schinke C; Arkansas Children's Nutrition Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Thanendrarajan S; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Zangari M; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Janz S; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Barlogie B; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Van Rhee F; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Tricot G; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Shaughnessy JD; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA.
  • Zhan F; Myeloma Center, Department of Internal Medicine, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 W. Markham St. Slot# 508, Little Rock, AR, 72205, USA. JDShaughnessy@uams.edu.
J Hematol Oncol ; 16(1): 70, 2023 06 29.
Article en En | MEDLINE | ID: mdl-37386588
Multiple myeloma is preceded by monoclonal gammopathy of undetermined significance (MGUS). Serum markers are currently used to stratify MGUS patients into clinical risk groups. A molecular signature predicting MGUS progression has not been produced. We have explored the use of gene expression profiling to risk-stratify MGUS and developed an optimized signature based on large samples with long-term follow-up. Microarrays of plasma cell mRNA from 334 MGUS with stable disease and 40 MGUS that progressed to MM within 10 years, was used to define a molecular signature of MGUS risk. After a three-fold cross-validation analysis, the top thirty-six genes that appeared in each validation and maximized the concordance between risk score and MGUS progression were included in the gene signature (GS36). The GS36 accurately predicted MGUS progression (C-statistic is 0.928). An optimal cut-point for risk of progression by the GS36 score was found to be 0.7, which identified a subset of 61 patients with a 10-year progression probability of 54.1%. The remainder of the 313 patients had a probability of progression of only 2.2%. The sensitivity and specificity were 82.5% and 91.6%. Furthermore, combination of GS36, free light chain ratio and immunoparesis identified a subset of MGUS patients with 82.4% risk of progression to MM within 10 years. A gene expression signature combined with serum markers created a highly robust model for predicting risk of MGUS progression. These findings strongly support the inclusion of genomic analysis in the management of MGUS to identify patients who may benefit from more frequent monitoring.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gammopatía Monoclonal de Relevancia Indeterminada / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Gammopatía Monoclonal de Relevancia Indeterminada / Mieloma Múltiple Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido